These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 33840996)

  • 21. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.
    He J; Hu L; Huang X; Wang C; Zhang Z; Wang Y; Zhang D; Ye W
    Int J Antimicrob Agents; 2020 Aug; 56(2):106055. PubMed ID: 32534187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?
    Mamber SW; Krakowka S; Osborn J; Saberski L; Rhodes RG; Dahlberg AE; Pond-Tor S; Fitzgerald K; Wright N; Beseme S; McMichael J
    mSphere; 2020 May; 5(3):. PubMed ID: 32404512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking.
    Yu R; Chen L; Lan R; Shen R; Li P
    Int J Antimicrob Agents; 2020 Aug; 56(2):106012. PubMed ID: 32389723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant.
    Pachetti M; Marini B; Benedetti F; Giudici F; Mauro E; Storici P; Masciovecchio C; Angeletti S; Ciccozzi M; Gallo RC; Zella D; Ippodrino R
    J Transl Med; 2020 Apr; 18(1):179. PubMed ID: 32321524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.
    Wu C; Liu Y; Yang Y; Zhang P; Zhong W; Wang Y; Wang Q; Xu Y; Li M; Li X; Zheng M; Chen L; Li H
    Acta Pharm Sin B; 2020 May; 10(5):766-788. PubMed ID: 32292689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period.
    Kissler SM; Tedijanto C; Goldstein E; Grad YH; Lipsitch M
    Science; 2020 May; 368(6493):860-868. PubMed ID: 32291278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nutritional recommendations for CoVID-19 quarantine.
    Muscogiuri G; Barrea L; Savastano S; Colao A
    Eur J Clin Nutr; 2020 Jun; 74(6):850-851. PubMed ID: 32286533
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
    Sanders JM; Monogue ML; Jodlowski TZ; Cutrell JB
    JAMA; 2020 May; 323(18):1824-1836. PubMed ID: 32282022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of COVID-19 for patients with obesity.
    Kassir R
    Obes Rev; 2020 Jun; 21(6):e13034. PubMed ID: 32281287
    [No Abstract]   [Full Text] [Related]  

  • 30. Endocrine and metabolic link to coronavirus infection.
    Bornstein SR; Dalan R; Hopkins D; Mingrone G; Boehm BO
    Nat Rev Endocrinol; 2020 Jun; 16(6):297-298. PubMed ID: 32242089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID 19 and the Patient with Obesity - The Editors Speak Out.
    Ryan DH; Ravussin E; Heymsfield S
    Obesity (Silver Spring); 2020 May; 28(5):847. PubMed ID: 32237212
    [No Abstract]   [Full Text] [Related]  

  • 32. Obesity and its Implications for COVID-19 Mortality.
    Dietz W; Santos-Burgoa C
    Obesity (Silver Spring); 2020 Jun; 28(6):1005. PubMed ID: 32237206
    [No Abstract]   [Full Text] [Related]  

  • 33. COVID-19-Related School Closings and Risk of Weight Gain Among Children.
    Rundle AG; Park Y; Herbstman JB; Kinsey EW; Wang YC
    Obesity (Silver Spring); 2020 Jun; 28(6):1008-1009. PubMed ID: 32227671
    [No Abstract]   [Full Text] [Related]  

  • 34. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.
    Elfiky AA
    Life Sci; 2020 Jul; 253():117592. PubMed ID: 32222463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Covid-19: risk factors for severe disease and death.
    Jordan RE; Adab P; Cheng KK
    BMJ; 2020 Mar; 368():m1198. PubMed ID: 32217618
    [No Abstract]   [Full Text] [Related]  

  • 36. Covid-19: control measures must be equitable and inclusive.
    Berger ZD; Evans NG; Phelan AL; Silverman RD
    BMJ; 2020 Mar; 368():m1141. PubMed ID: 32198146
    [No Abstract]   [Full Text] [Related]  

  • 37. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.
    Liu J; Cao R; Xu M; Wang X; Zhang H; Hu H; Li Y; Hu Z; Zhong W; Wang M
    Cell Discov; 2020; 6():16. PubMed ID: 32194981
    [No Abstract]   [Full Text] [Related]  

  • 38. COVID-19: consider cytokine storm syndromes and immunosuppression.
    Mehta P; McAuley DF; Brown M; Sanchez E; Tattersall RS; Manson JJ;
    Lancet; 2020 Mar; 395(10229):1033-1034. PubMed ID: 32192578
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical considerations for patients with diabetes in times of COVID-19 epidemic.
    Gupta R; Ghosh A; Singh AK; Misra A
    Diabetes Metab Syndr; 2020; 14(3):211-212. PubMed ID: 32172175
    [No Abstract]   [Full Text] [Related]  

  • 40. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Yao X; Ye F; Zhang M; Cui C; Huang B; Niu P; Liu X; Zhao L; Dong E; Song C; Zhan S; Lu R; Li H; Tan W; Liu D
    Clin Infect Dis; 2020 Jul; 71(15):732-739. PubMed ID: 32150618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.